There are several bs-Abs that have the ability to alter various aspects of cancer TME, including tumor proliferation, angiogenesis, metastasis, and immunosuppression by targeting signaling pathways such as HER1, HER2, HER3, EGFR, TGF-β and VEGF. This evidence concerns the gene TGFB1 and neoplasm.